164 related articles for article (PubMed ID: 21528523)
1. [Active surveillance of prostatic cancer].
Vasarainen H; Ruutu M; Rannikko A
Duodecim; 2011; 127(6):593-9. PubMed ID: 21528523
[TBL] [Abstract][Full Text] [Related]
2. [Management of prostate cancer with indolent biological potential: from watchful waiting to active surveillance].
Leibovici D; Lindner A; Stay K; Zisman A
Harefuah; 2006 Oct; 145(10):763-7, 781, 780. PubMed ID: 17111715
[TBL] [Abstract][Full Text] [Related]
3. Active surveillance with selective delayed intervention: walking the line between overtreatment for indolent disease and undertreatment for aggressive disease.
Klotz LH
Can J Urol; 2005 Feb; 12 Suppl 1():53-7; discussion 101-2. PubMed ID: 15780167
[TBL] [Abstract][Full Text] [Related]
4. Early outcomes of active surveillance for localized prostate cancer.
Hardie C; Parker C; Norman A; Eeles R; Horwich A; Huddart R; Dearnaley D
BJU Int; 2005 May; 95(7):956-60. PubMed ID: 15839912
[TBL] [Abstract][Full Text] [Related]
5. Psychological aspects of active surveillance.
van den Bergh RC; Korfage IJ; Bangma CH
Curr Opin Urol; 2012 May; 22(3):237-42. PubMed ID: 22357407
[TBL] [Abstract][Full Text] [Related]
6. Active surveillance with selective delayed intervention for favorable risk prostate cancer: clinical experience and a 'number needed to treat' analysis.
Klotz LH; Nam RK
Can J Urol; 2006 Feb; 13 Suppl 1():48-55. PubMed ID: 16526983
[TBL] [Abstract][Full Text] [Related]
7. Prostate cancer death of men treated with initial active surveillance: clinical and biochemical characteristics.
Krakowsky Y; Loblaw A; Klotz L
J Urol; 2010 Jul; 184(1):131-5. PubMed ID: 20478589
[TBL] [Abstract][Full Text] [Related]
8. Active surveillance with selective delayed intervention for favorable risk prostate cancer.
Klotz L
Urol Oncol; 2006; 24(1):46-50. PubMed ID: 16414494
[TBL] [Abstract][Full Text] [Related]
9. Active surveillance for low-risk prostate cancer: selection of patients and predictors of progression.
Dall'Era MA; Konety BR
Nat Clin Pract Urol; 2008 May; 5(5):277-83. PubMed ID: 18285752
[TBL] [Abstract][Full Text] [Related]
10. Factors that influence patient enrollment in active surveillance for low-risk prostate cancer.
Gorin MA; Soloway CT; Eldefrawy A; Soloway MS
Urology; 2011 Mar; 77(3):588-91. PubMed ID: 21215429
[TBL] [Abstract][Full Text] [Related]
11. Active surveillance with selective delayed intervention using PSA doubling time for good risk prostate cancer.
Klotz L
Eur Urol; 2005 Jan; 47(1):16-21. PubMed ID: 15582244
[TBL] [Abstract][Full Text] [Related]
12. Cost comparison between watchful waiting with active surveillance and active treatment of clinically localized prostate cancer.
Corcoran AT; Peele PB; Benoit RM
Urology; 2010 Sep; 76(3):703-7. PubMed ID: 20381846
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of localized prostate cancer having a good prognosis may cause more harm than benefit].
Ruutu M; Rannikko A; Malmi H; Vasarainen H; Mikkola A
Duodecim; 2009; 125(14):1516-23. PubMed ID: 19711574
[TBL] [Abstract][Full Text] [Related]
14. Active surveillance of early prostate cancer: rationale, initial results and future developments.
Parker C
Prostate Cancer Prostatic Dis; 2004; 7(3):184-7. PubMed ID: 15224088
[TBL] [Abstract][Full Text] [Related]
15. [Active surveillance for low-risk prostate cancer].
Ploussard G
Rev Prat; 2013 Apr; 63(4):485-8. PubMed ID: 23682474
[TBL] [Abstract][Full Text] [Related]
16. Active surveillance for favorable risk prostate cancer: rationale, risks, and results.
Klotz L
Urol Oncol; 2007; 25(6):505-9. PubMed ID: 18047961
[TBL] [Abstract][Full Text] [Related]
17. Active surveillance for good risk prostate cancer: rationale, method, and results.
Klotz LH
Can J Urol; 2005 Jun; 12 Suppl 2():21-4. PubMed ID: 16018828
[TBL] [Abstract][Full Text] [Related]
18. Conventional treatments of localized prostate cancer.
Zerbib M; Zelefsky MJ; Higano CS; Carroll PR
Urology; 2008 Dec; 72(6 Suppl):S25-35. PubMed ID: 19095125
[TBL] [Abstract][Full Text] [Related]
19. Active surveillance monitoring more stringent in updated NCCN Guidelines for prostate cancer.
J Natl Compr Canc Netw; 2011 May; 9(5):xxxvii-xlii. PubMed ID: 21739727
[No Abstract] [Full Text] [Related]
20. Active surveillance with selective delayed intervention is the way to manage 'good-risk' prostate cancer.
Klotz L
Nat Clin Pract Urol; 2005 Mar; 2(3):136-42; quiz 1 p following 149. PubMed ID: 16474710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
